Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
By Shannon Blair on
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
We want to hear what you’re working on.
We partner with founders from the beginning, supporting entrepreneurs from concept through early growth.
Rev1 Gateway
1590 North High St.
Columbus OH 43201
Get Directions
Rev1 Labs
1275 Kinnear Rd.
Columbus, Ohio 43212
Get Directions
©2020 Rev1 Ventures. All rights reserved.
Privacy Policy